This trial is to test the safety of DZ-002 and to see what dose is tolerated by patients with solid tumors. They will also assess how the drug works against tumors.
2 Primary · 7 Secondary · Reporting Duration: 24 months
Experimental Treatment
55 Total Participants · 1 Treatment Group
Primary Treatment: DZ-002 · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: